All News

PsA.Xray_.Erosion.Cup_.jpg

FUTURE 5 - Secukinumab and Less Radiographic Progression in Psoriatic Arthritis

d Jack Cush, MD

The FUTURE 5 trial studied the effect of secukinumab (SEC) on radiographic progression through 52 weeks in patients with active psoriatic arthritis (PsA) and found that SEC was clinically and radiographically superior to placebo (PBO).

Patients received s.c. secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load regimens or placebo at baseline, at weeks 1, 2 and 3 and every 4 weeks starting at week 4. The majority (87%) of patients enrolled at baseline remained in the study for 52 weeks.

Read Article
early.RA_.jpg

Antibiotics Increase Rheumatoid Risk - Again

d Jack Cush, MD

Another UK study has suggested that prior use of antibiotics increases the risk of developing rheumatoid arthritis (RA).

Read Article
IPF.lancet.jpg

ILD Patients At Risk for Autoimmune Disease

d Jack Cush, MD

Patients diagnosed with interstitial pneumonia with autoimmune features (IPAF) are at an increased risk of developing a systemic autoimmune rheumatic disease (ARD).

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Women Take Over Rheumatology (10.4.19)

d Jack Cush, MD

Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.

Read Article
OP_0.jpg

ASBMR Recommendations on Secondary Fracture Prevention

d Jack Cush, MD

The American Society for Bone and Mineral Research has developed multistakeholder consensus clinical recommendations for the prevention of secondary fractures for those aged 65 years and older after an initial hip or vertebral fracture.

Read Article

Note to Colleague: How can you possibly diagnose and treat ankylosing spondylitis in a patient with polyarthralgias, +B27 but nothing else (no enthesitis, Pso, IBD, Abnl Schobers and neg SI films)?? The diagnosis (poor sleep, tender points) was obvious. You know who you are

Dr. John Cush RheumNow ( View Tweet)

Osteoarthritis Initiative studied 4344 knee OA looking at bulge sign (12.7%) & patellar tap (2%); 3.3% had both. Bulge sign increased risk of freq knee pain (OR 1.31) & TKR [OR 1.47); developing a bulge sign had incr risk of same & Xray worsening (OR 1.67) https://t.co/3HtBrkzAtk

Links:

Dr. John Cush RheumNow ( View Tweet)

225 very early RA in abatacept AVERT study - 44% had high baseline MRI inflammation. With High MRI inflammation, combo ABA+MTX was better than MTX at 12 mos remission by SDAI (45% vs 16%). Pts w/ low baseline MRI inflammation, remission rates did the same https://t.co/A9MRSWaKGB

Links:

Dr. John Cush RheumNow ( View Tweet)

Take the Good with the Bad? Study of 179 RA pts achieving remission on TCZ- SC 162 mg qwk randomized to continue qWk or space out to q2Wk -- Weekly Actemra better maintained remission (90% versus 73%; P = 0.004), but then again 73% did well w/ spacing EOW. https://t.co/Tcb2WwCbc2

Links:

Dr. John Cush RheumNow ( View Tweet)

2/ ...but practicing docs use such criteria to: 1. Diagnose patients in clinical practice 2. Teach disease definitions to trainees Perhaps we should stop making classification criteria entirely and just accept that the field needs diagnostic criteria instead? I

Mike Putman EBRheum ( View Tweet)

Arthritis Care & Research Editors Pick: Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database → https://t.co/wWjIrVHqqJ

Links:

American College of Rheumatology ACRheum ( View Tweet)

T2T in Lupus Nephritis aims for less proteinuria, Study of 87 pts with class III/IV LN compared goal of urine protein/creat ratio(UPCR) < 0.5 to stringent < 0.15, Latter assoc w/ lower renal flares (HR  0.16), less CKD (HR 0.19), more MMF use (HR = 7.26) https://t.co/0LSXTiUAaV

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up! Women are Taking Over Rheumatology. Watch is on the website>> https://t.co/YuDVm1lLXZ or listen to thoe podcast on iTunes, Stitcher, Overcast or SoundCloud >> https://t.co/A8FzdUaEk2

Links:

Dr. John Cush RheumNow ( View Tweet)

Looking forward to giving plenary talk at #ACR2019 at 11AM Sunday on practical aspects of vaccines(flu/pneumo/VZV) for autoimmune pts @paijournal @IDSA @RheumNow @HealioRheum @AdamJBrownMD @ELittlejohnDO @RulaHajjAliMD https://t.co/UIYBIBDeSe

Links:

Leonard Calabrese LCalabreseDO ( View Tweet)

Get the FREE RheumaKnowledgy Card - a pocket guide/aid to the diagnosis, testing and Rx of Rheumatologic, autoimmune and other MSK complaints. https://t.co/oMa3qzh7xt

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM: Synovial Chondromatosis. A 46-year-old woman with rheumatoid arthritis presented with pain and swelling in both knees. Radiographic findings were consistent with synovial chondromatosis. https://t.co/9jMzE0fuNE

Links:

Dr. John Cush RheumNow ( View Tweet)

N. Zealand study shows their cost of knee OA was $200 million in 2013; and without any changes in the standards of care, this isprojected to increase to $370 million by 2038. (includes an additional 4,000 TKRs per year by 2038). https://t.co/B1awh1ky1B

Links:

Dr. John Cush RheumNow ( View Tweet)

Claims study of RA, PsA, AS/SpA patients on TNF inhibitors shows a comparison of 31,527 MTX vs 34,651 TNFi initiators. MTX was D/C sooner in PsA & AS [aHR 1.10, 1.23) vs RA pts. Concomitant MTX reduced risk of TNFi D/C in all [aHR 0.85, 0.81, 0.79] https://t.co/0l2J2FDsUm

Links:

Dr. John Cush RheumNow ( View Tweet)

Might Vioxx make a backdoor comeback? 2017 Vioxx went off patent, now a small pharma has applied to the FDA for orphan drug approval of rofecoxib (& etoricoxib) to treat hemophiliac arthropathy (large unmet need). Say it aint so! https://t.co/kENHHhcyIT https://t.co/QpDNiaCZyz

Links:

Dr. John Cush RheumNow ( View Tweet)

Choi and colleagues have shown that allopurinol-associated severe cutaneous adverse reactions are higher with Heart (RR 1.44) and Renal (11 fold) disease. Initating low-dosage allopurinol may substantially mitigate this risk. https://t.co/gyj7Xn3uhx

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×